Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $34.36, Implies 55% Upside
Nurix Therapeutics' average price target increased from $33.93 to $34.36 by 14 analysts, with a range of $25 to $45. This implies a 55% upside from the Oct. 12 closing price. The consensus rating remains 'Buy' with 13 Buys, 1 Hold, and 0 Sells.
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 7:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Decision brief
The 30-second read
Low
01
Why it matters
Analyst target lift signals confidence but lacks a concrete catalyst.
02
Market read
A modest analyst upgrade with limited immediate trading impact.
03
What to watch
No new clinical data or partnership announced; price target change alone may not sustain a rally.
Relevance 5/10Novelty 5/10Timing: today
Background
Nurix Therapeutics is a clinical‑stage biotech focused on targeted protein degradation.
Market effects
Sector
Minimal; reflects broader analyst optimism in biotech.
Regional
None
Global
Low
Counterpoint
What could challenge this read
Target raise may be premature if upcoming trial data disappoints.
Key entities
- companyNurix Therapeutics, Inc.
Biotech firm receiving a higher consensus price target.
